Combination drug therapy articles within Nature Communications

Featured

• Article
  17 November 2022 | Open Access

  A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer

  Neoadjuvant therapy is recommended for patients with locally advanced breast cancer. Here the authors report the results of a phase 2 clinical trial of oral neoadjuvant therapy with pyrotinib (pan-HER tyrosine kinase inhibitor), letrozole (aromatase inhibitor) and dalpiciclib (CDK4/6 inhibitor) in patients with treatment-naïve and stage II-III triple positive breast cancer.

  • Nan Niu
  • , Fang Qiu
  •  & Caigang Liu

• Article
  01 March 2021 | Open Access

  Photocatalysis-mediated drug-free sustainable cancer therapy using nanocatalyst

  Nanoparticles have been used to reduce the toxicity associated with chemotherapeutic agents. Here, the authors report a Z-scheme SnS_1.68-WO_2.41 nanocatalyst for photocatalytic generation of oxidative holes and hydrogen molecules for drug-free therapeutic strategy.

  • Bin Zhao
  • , Yingshuai Wang
  •  & Qianjun He

• Article
  18 May 2016 | Open Access

  Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies

  Antimalarial chemotherapy relies on combination therapies (ACTs) consisting of an artemisinin derivative and a partner drug. Here, the authors study the effects of globally prevalent mutations in a multidrug resistance transporter (PfMDR1) on the parasite’s susceptibility to ACT drugs.

  • M. Isabel Veiga
  • , Satish K. Dhingra
  •  & David A. Fidock

• Article
  28 September 2015 | Open Access

  Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer

  Predicting combinations of chemotherapeutic drugs that act synergistically is challenging. Here the authors take a computational approach to predict synergistic pairs, validate novel pairs using several cancer cell lines, and assess toxicity in a zebrafish xenograft model.

  • Yi Sun
  • , Zhen Sheng
  •  & Zhiwei Cao

• Article
  11 February 2015 | Open Access

  Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition

  Adaptive resistance is an emerging cause of chemotherapy failure in cancer. Here the authors show that adaptive resistance to taxanes is mediated by the upregulation of SFK/Hck survival signalling, and that sequential administration of taxanes and SFK/Hck inhibition restores tumor cell chemosensitivity.

  • Aaron Goldman
  • , Biswanath Majumder
  •  & Shiladitya Sengupta

• Article | 02 December 2014

  Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

  Despite the treatment efficacy of combining BRAF and MEK inhibitors, a third of BRAF-mutant metastatic melanoma patients treated with this therapy progress within 6 months. Here, the authors sequence tumours from patients with BRAF^V600-mutant melanoma metastases and identify mutations that confer resistance to combination therapy.

  • Georgina V. Long
  • , Carina Fung
  •  & Helen Rizos

• Article
  26 November 2014 | Open Access

  Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis

  Several drug combinations with different properties are used for malaria treatment. Here, Okell et al. use a mathematical model to simulate malaria transmission and treatment with two drug combinations in Africa, and find that locally optimized policies can be highly cost effective for reducing malaria burden.

  • Lucy C. Okell
  • , Matthew Cairns
  •  & Azra C. Ghani